QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-halozyme-therapeutics-maintains-65-price-target

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Buy and maintains $65 ...

 benchmark-maintains-buy-on-halozyme-therapeutics-raises-price-target-to-60

Benchmark analyst Robert Wasserman maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raises the price target from...

 halozymes-ocrevus-sc-gets-european-approval-for-multiple-sclerosis-treatment

Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced that Roche received European Commission (EC) mar...

 hc-wainwright--co-reiterates-buy-on-halozyme-therapeutics-maintains-65-price-target

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Buy and maintains $65 ...

 novavax-and-agios-pharmaceuticals-were-among-the-10-biggest-mid-cap-gainers-last-week-june-1-june-7-are-these-in-your-portfolio

Mid-cap stocks saw significant gains last week, with top performers like AGIO, VRNT, and NVAX, causing analysts to raise their ...

 wells-fargo-maintains-overweight-on-halozyme-therapeutics-raises-price-target-to-58

Wells Fargo analyst Mohit Bansal maintains Halozyme Therapeutics (NASDAQ:HALO) with a Overweight and raises the price target...

 hc-wainwright--co-maintains-buy-on-halozyme-therapeutics-raises-price-target-to-65

HC Wainwright & Co. analyst Mitchell Kapoor maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raises the pric...

 piper-sandler-downgrades-halozyme-therapeutics-to-neutral-raises-price-target-to-51

Piper Sandler analyst Joseph Catanzaro downgrades Halozyme Therapeutics (NASDAQ:HALO) from Overweight to Neutral and raises ...

 halozyme-therapeutics-13-on-thursday-whats-going-on

Halozyme Therapeutics surges as it raises FY24 guidance, driven by increased revenue projections and a new European patent for ...

 halozyme-receives-issuance-of-new-european-patent-for-enhanze-drug-delivery-platform-will-be-validated-in-37-european-countries-and-expires-on-march-6-2029

Conference Call Scheduled for Thursday, June 6 at 5:30am PT/8:30am ETSAN DIEGO, June 5, 2024 /PRNewswire/ -- Halozyme Therapeut...

 hc-wainwright--co-reiterates-buy-on-halozyme-therapeutics-maintains-50-price-target

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Buy and maintains $50 ...

 hc-wainwright--co-reiterates-buy-on-halozyme-therapeutics-maintains-50-price-target

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Buy and maintains $50 ...

 halozyme-discloses-that-bristol-myers-squibb-received-updated-action-date-from-us-fda-for-subcutaneous-nivolumab-co-formulated-with-enhanze-halozymes-proprietary-recombinant-human-hyaluronidase-enzyme-the-updated-goal-date-is-december-29-2024

Halozyme announced that Bristol Myers Squibb was reassigned a Prescription Drug User Fee Act goal date from the U.S. Food and D...

 jmp-securities-maintains-market-outperform-on-halozyme-therapeutics-lowers-price-target-to-71

JMP Securities analyst Jason Butler maintains Halozyme Therapeutics (NASDAQ:HALO) with a Market Outperform and lowers the pr...